ClinicalTrials.gg
CompletedNCT01520909PETIT2Updated Mar 10, 2015Results posted

Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.

A Phase 3 interventional study of Eltrombopag and Placebo in Idiopathic Thrombocytopenic Purpura, sponsored by GlaxoSmithKline. Completed at 51 sites in 13 countries. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2015-03-10.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
92
Allocation
Randomized
Ages
1 Year to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic — 7 open to participants now, 7 under way, none of them phase 3. eltrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
10th of 36
92 · median 40
Started
2012
with 3 others
Phase 3
9 of 36
none open now
Registered
11th of 36
by date
Lead sponsor
9 of 36
GlaxoSmithKline

Among the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 10th largest by enrollment, is one of 4 that started in 2012, is one of 9 in phase 3, and was the 11th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

7 of the 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 1 Year to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing eltrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the efficacy, safety and tolerability of eltrombopag in children with previously treated chronic immune thrombocytopenia who are between 1 and 17 years of age. This is a 2 part study. In part 1, patients will be randomized to receive either eltrombopag or placebo for 13 weeks. All patients who complete part 1 will enter part 2. In part 2, all patients will receive 24 weeks of eltrombopag.

Read the detailed description

This is a two part, double-blind, randomized, placebo-controlled and open-label Phase III study to investigate the efficacy, safety and tolerability of eltrombopag in pediatric patients with previously treated chronic ITP. In Part 1, patients will be randomized to receive eltrombopag or placebo in a 13-week double-blind, placebo-controlled treatment period. After completing Part 1, patients will begin Part 2, in which they will receive eltrombopag in an open-label manner during a 24-week treatment period.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • immune thrombocytopenic purpura
  • pediatrics
  • chronic ITP
  • idiopathic thrombocytopenic purpura
  • eltrombopag
  • Chronic Immune Thrombocytopenia
  • platelet disorder
  • thrombocytopenia
04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written must be obtained from the patient's guardian and accompanying informed assent from the patient (for children over 6 years old)
  • Patients must be between 1 year and \<18 years of age at Day 1
  • Patients will have a confirmed diagnosis of chronic ITP for at least 1 year, at screening, according to the guidelines published in the International Working Group Report
  • A peripheral blood smear or bone marrow examination will support the diagnosis of ITP with no evidence of other causes of thrombocytopenia.
  • Patients must be or have relapsed after at least one prior ITP therapy, or patients must be unable, for a medical reason, to continue other ITP treatments.
  • Patients must have a Day 1 (or within 48 hours prior) count \<30 Gi/L.
  • Previous therapy for ITP with immunoglobulins (IVIg and anti-D) must have been completed at least 2 weeks prior to Day 1, or these therapies must have been completed at least 1 week prior to Day 1 and have been clearly ineffective.
  • Previous treatment for ITP with splenectomy, rituximab and cyclophosphamide must have been completed at least 4 weeks prior to Day 1.
  • Patients treated with concomitant ITP medication (e.g. or azathioprine) must be receiving a dose that has been stable for at least 4 weeks prior to Day 1.
  • Patients must have a complete blood count (CBC) not suggestive of another hematological disorder.
  • Patients must have the following laboratory results:
  • international normalized ratio (INR) and activated partial thromboplastin time (aPTT) within 80 to 120% of the normal range.
  • clinical chemistries that do NOT exceed the reference range by more than 20% for the following: creatinine, , AST, total , and alkaline phosphatase.
  • total albumin that is not below the lower limit of normal by more than 10%.
  • Female patients of (after menarche) must:
  • have a negative pregnancy test within 24 hours of first dose of study treatment,
  • agree and be able to provide a blood or urine specimen for pregnancy testing during the study,
  • agree to use effective during the study and for 28 days following the last dose of study treatment, and not be lactating.
  • Male patients with a female partner of childbearing potential must agree to use effective contraception from 2 weeks prior to administration of the first dose of study treatment until 3 months after the last dose of study treatment.
  • In France, a patient will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.

Exclusion criteria

Exclusion Criteria:

  • Patients with any abnormality, other than ITP, identified on the screening examination or any other medical condition or circumstance, which in the opinion of the investigator makes the patient unsuitable for participation in the study or suggests another primary diagnosis (e.g. Thrombocytopenia is secondary to another disease).
  • Patients with concurrent or past malignant disease, including myeloproliferative disorder.
  • Patients expected not to be suitable for continuation of their current therapy for at least 13 additional weeks.
  • Patients with a history of agglutination abnormality that prevents reliable measurement of platelet counts.
  • Patients with a diagnosis of secondary immune thrombocytopenia, including those with laboratory or clinical evidence of infection, anti-phospholipid antibody syndrome, chronic infection, virus infection, or any evidence of active hepatitis at the time of subject screening.
  • Patients with Evans syndrome ( thrombocytopenia and autoimmune hemolysis).
  • Patients with known inherited thrombocytopenia (e.g. MYH9 disorders).
  • Patients treated with any medication that affects platelet function (including but not limited to aspirin, clopidogrel and/or NSAIDS) or anti-coagulants for >3 consecutive days within 2 weeks of Day 1.
  • Patients who have received treatment with an drug within 30 days or 5 half-lives (whichever is longer) preceding Day 1.
  • Patients who have previously received eltrombopag or any other thrombopoietin receptor agonist.
  • Any patient considered to be a child in care, defined as one who has been placed under the control or protection of an agency, organization, institution or entity by the courts, the government or a government body, acting in accordance with powers conferred on them by law or regulation. This can include a child cared for by foster parents or living in a care home or institution, provided that the arrangement falls within the definition above. The definition of a child in care does not include a child who is adopted or who has an appointed legal guardian.
  • Patients who have a known immediate or delayed reaction or idiosyncrasy to drugs chemically related to eltrombopag or that contraindicates their participation.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder, or other conditions that could interfere with the patient's safety or compliance to the study procedures.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
92 participants (actual)

Study arms

  • Experimental
    Eltrombopag plus standard of care

    Part 1, double-blind treatment group

    Drug: Eltrombopag

  • Placebo comparator
    Placebo plus standard of care

    Part 1, double-blind treatment group

    Drug: Placebo

  • Experimental
    Eltrombopag plus standard of care (Part 2 open-label)

    Part 2, open-label

    Drug: Eltrombopag

Interventions

  • Thrombopoietin receptor agonist

  • DrugPlacebo

    Placebo with no active pharmaceutical ingredient

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1

    Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.

    Time frame: From Week 5 up to Week 12 of Part 1

Secondary outcomes

  1. Percentage of Responders

    Percentage of participants who responded (defined as platelet count \>= 50 Gi/L in absence of rescue) at least once up to week 12 of Part 1 (Odds of achieving a platelet count \>=50 Gi/L during the first 12 weeks of Part 1)

    Time frame: From Week 1 up to Week 12 of Part 1

  2. Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1

    Participants who achieved a platelet count \>=50 Gi/L at any time during the first 12 weeks of Part 1 were reported.

    Time frame: From Baseline up to Week 12 of Part 1

  3. Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1

    Participants who achieved a platelet count \>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.

    Time frame: From Baseline up to Week 6 of Part 1

  4. Weighted Mean Platelet Count

    The weighted mean platelet count is defined as "the area under the platelet-time curve divided by the duration of the study (12 weeks)". Weighted mean platelet counts from baseline to week 12 of the randomized period was compared between placebo and eltrombopag using an analysis of covariance model (ANCOVA) adjusting for baseline platelet count and age cohort. For each subject the area between two adjacent visits with platelet counts was calculated. The area was calculated for all pairs of adjacent visits starting at Day 1 of randomized period and then the total sum of all the areas was divided by the total duration of time during the randomized period. For each subject, this method calculates an 'average' platelet count and it allows the possibility that subjects may have had different number of assessments during different times relative to baseline.

    Time frame: Baseline and Week 12 of Part 1

  5. Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1

    The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

    Time frame: From Baseline up to Week 12 of Part 1

  6. Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1

    Rescue treatment is defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.

    Time frame: From Baseline up to Week 12 of Part 1

  7. Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1

    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline was defined as the Day 1 assessment or the latest possible screening assessment.

    Time frame: From Baseline through Follow-up of Part 1

  8. Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2

    Participants who achieved a platelet count \>=50 Gi/L at any time during Part 2 (up to Week 24) were reported.

    Time frame: From Baseline up to Week 24 of Part 2

  9. Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2

    Platelet response was analyzed after Week 4 for the eltrombopag-only period to allow participants who had been randomized to placebo in the Randomized Period time to escalate to their optimal dose of eltrombopag. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

    Time frame: From Week 4 up to Week 24 of Part 2

  10. Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2

    The maximum duration for which a participant continuously maintained a platelet count of \>=50 Gi/L was calculated and summarized for the 24 weeks of eltrombopag dosing (Part 2). Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

    Time frame: From Baseline up to Week 24 of Part 2

  11. Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy

    Participants who discontinued or had a sustained reduction of a baseline immune (idiopathic) thrombocytopenic purpura (ITP) medication during the 24 weeks of Part 2 (Open-Label Period) and without requiring subsequent rescue therapy. For participants randomized to placebo in Part 1, Baseline is defined as Week 13 of Part 1. For participants randomized to eltrombopag in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction was defined as a reduction for 4 weeks or more.

    Time frame: From Baseline up to Week 24 of Part 2

  12. Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2

    Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.

    Time frame: From Baseline up to Week 24 of Part 2

  13. Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the WHO Bleeding Scale During Part 2

    The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO Grades were dichotomized into the following categories: no bleeding = Grade 0; any bleeding = Grade 1 to 4; no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4.

    Time frame: From Baseline of Part 2 through Follow-up

  14. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Day 1 of Treatment up to Week 13 of Part 1+ 1 day

  15. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2

    An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening; requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

    Time frame: From Day 1 of Part 2 up to Week 24 of Part 2 + 1 day

  16. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 1

    Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: Grade 0 (G0), none; Grade 1 (G1), mild; Grade 2 (G2), moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling. Clinical chemistry parameters included: aspartate amino transferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, alanine amino transferase (ALT), prothrombin international normalized ratio (PT INR), activated partial thromboplastin time (APTT), and creatinine. The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as Baseline. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.

    Time frame: From Baseline up to Week 13 of Part 1

  17. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2

    Clinical chemistry parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: AST, ALP, total bilirubin, albumin, ALT, and creatinine. For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For serum creatinine, the value taken at Week 13 of Part 1 will be used as BL. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as BL. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.

    Time frame: From Baseline (BL) of Part 2 through Follow-up

  18. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 1

    Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.

    Time frame: From Baseline up to Week 13 of Part 1

  19. Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2

    Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none, G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.

    Time frame: From Baseline up to Week 24 of Part 2 and Follow-up Weeks 1 to 4 (up to Study Week 41)

  20. Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 1

    Vital sign measurements were taken before any blood draws and included systolic blood pressure(SBP), diastolic blood pressure(DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard reference ranges RR as reference range high(RRH) and reference range low(RRL). The Baseline(BL) value is defined as the value taken at Day 1 or if missing, the latest non-missing SCR value. RR for Blood Pressure (mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120;, DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR(bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.

    Time frame: From Screening (SCR) up to Week 13 of Part 1

  21. Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 2

    Vital sign measurements were taken before any blood draw and included systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard RR as reference range high(RRH) and reference range low(RRL) from SCR up to Week 24 of Part 2 and from Follow-up Week 1 to Week 4. RR for Blood Pressure(mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120; DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR (bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.

    Time frame: From Week 1 up to Week 24 of Part 2 and Follow-up Week 1 to Week 4 (up to Week 41)

  22. Number of Participants With a Change in Visual Acuity Since Baseline at Week 12 of Part 1

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No (no change from Baseline), Not Clinically Significant (NCS), Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

    Time frame: Baseline and Week 12 of Part 1

  23. Number of Participants With a Change in Visual Acuity Since Baseline at Week 24 of Part 2

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

    Time frame: Baseline and Week 24 of Part 2

  24. Number of Participants With a Change in Visual Acuity Since Baseline at Follow-Up Week 24

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

    Time frame: Baseline and Follow-Up Week 24 (Study Week 61)

  25. Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 12 of Part 1

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 12 of Part 1 are presented. Change due to cataracts is categorized as "Yes" or "No."

    Time frame: Baseline and Week 12 of Part 1

  26. Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 24 of Part 2

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 24 of Part 2 are presented. Change due to cataracts is categorized as "Yes" or "No.

    Time frame: Baseline and Week 24 of Part 2

  27. Number of Participants With Worsening Visual Acuity Due to Cataracts at Follow-Up Week 24

    The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Follow-up Week 24 are presented. Change due to cataracts is categorized as "Yes" or "No."

    Time frame: Baseline and Follow-Up Week 24 (Week 61)

  28. Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)

    Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. The AUC(0-t) for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)

  29. Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax

    Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Cmax is defined as the maximum observed concentration. The Cmax for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

    Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)

  30. Pharmacokinetic (PK) Assessments for Eltrombopag for Apparent Oral Clearance (CL/F) and Apparent Intercompartmental Clearance (Q/F)

    Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.

    Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)

  31. PK Assessments for Eltrombopag for Apparent Central Volume (Vc/F) and Apparent Peripheral Volume (Vp/F)

    Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Vc/F is defined as the volume of the central (e.g. plasma) compartment and Vp/F is defined as the volume of the peripheral compartment. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.

    Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)

  32. Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)

    Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Ka is defined as the absorption rate constant. This parameter is dose independent, and the population estimate Ka is reported.

    Time frame: Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)

07

Results

Posted Sep 29, 2014

Participant flow

Pediatric participants meeting eligibility criteria were enrolled into 3 cohorts depending upon age. Cohort 1 enrolled participants who were between 12 and 17 years old, Cohort 2 enrolled participants who were between 6 and 11 years old, and Cohort 3 enrolled participants who were between 1 and 5 years old.

Part 1 (Randomized Period)
Participant flow — Part 1 (Randomized Period)
MilestonePart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period)-EltrombopagPart 2 (Open-Label Period) Eltrombopag
Started29630
Completed28610
Not completed120
Withdrew: Adverse event120
Part 2 (Open-Label Period)-Eltrombopag
Participant flow — Part 2 (Open-Label Period)-Eltrombopag
MilestonePart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period)-EltrombopagPart 2 (Open-Label Period) Eltrombopag
Started0087
Completed0080
Not completed007
Withdrew: Adverse event004
Withdrew: Lack of efficacy002
Withdrew: Withdrawal by parent or guardian001

Outcome measures

PrimaryNumber of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1

Participants who achieved a platelet count \>=50 Gi/L for at least 6 out of 8 weeks, between Weeks 5 and 12 of Part 1, were reported.

Time frame:
From Week 5 up to Week 12 of Part 1
Reported as:
Number · Participants
Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1
ParticipantsPart 1 (Randomized Period)- PlaceboPart 1 (Randomized Period)-Eltrombopag
Number of Participants Achieving a Platelet Count >=50 Giga Cells Per Liter (Gi/L) for at Least 6 Out of 8 Weeks, Between Weeks 5 and 12 of Part 1125
Statistical analysis
  • Part 1 (Randomized Period)- Placebo vs Part 1 (Randomized Period)-Eltrombopag · Cochran-Mantel-Haenszel · p = <0.001 · Odds ratio (or): 17.96 · 95% CI 2.29 to 140.93The proportion of participants achieving platelet counts \>=50 Gi/L for those participants receiving eltrombopag versus placebo was compared.
SecondaryPercentage of Responders

Percentage of participants who responded (defined as platelet count \>= 50 Gi/L in absence of rescue) at least once up to week 12 of Part 1 (Odds of achieving a platelet count \>=50 Gi/L during the first 12 weeks of Part 1)

Time frame:
From Week 1 up to Week 12 of Part 1
Reported as:
Number · Percentage of participants
Percentage of Responders
Percentage of participantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Week 1015.9
Week 23.423.8
Week 3031.7
Week 46.936.5
Week 56.947.6
Week 66.938.1
Week 710.344.4
Week 83.444.4
Week 93.442.9
Week 103.452.4
Week 116.949.2
Week 123.458.7
Statistical analysis
  • Part 1 (Randomized Period)-Placebo vs Part 1 (Randomized Period) - Eltrombopag · Repeated measures model for binary data · p = <0.001 · Odds ratio (or): 25.33 · 95% CI 8.15 to 78.73Repeated measures model for binary data using Generalized linear mixed model
SecondaryNumber of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1

Participants who achieved a platelet count \>=50 Gi/L at any time during the first 12 weeks of Part 1 were reported.

Time frame:
From Baseline up to Week 12 of Part 1
Reported as:
Number · Participants
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1
ParticipantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 12 Weeks of Part 1647
SecondaryNumber of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1

Participants who achieved a platelet count \>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.

Time frame:
From Baseline up to Week 6 of Part 1
Reported as:
Number · Participants
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1
ParticipantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period)-Eltrombopag
Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1539
SecondaryWeighted Mean Platelet Count

The weighted mean platelet count is defined as "the area under the platelet-time curve divided by the duration of the study (12 weeks)". Weighted mean platelet counts from baseline to week 12 of the randomized period was compared between placebo and eltrombopag using an analysis of covariance model (ANCOVA) adjusting for baseline platelet count and age cohort. For each subject the area between two adjacent visits with platelet counts was calculated. The area was calculated for all pairs of adjacent visits starting at Day 1 of randomized period and then the total sum of all the areas was divided by the total duration of time during the randomized period. For each subject, this method calculates an 'average' platelet count and it allows the possibility that subjects may have had different number of assessments during different times relative to baseline.

Time frame:
Baseline and Week 12 of Part 1
Reported as:
Mean · Gi/L
Weighted Mean Platelet Count
Gi/LPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Baseline14.2 ± 8.0114.0 ± 8.09
Week 1223.7 ± 19.5663.9 ± 46.68
SecondaryMaximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1

The maximum duration for which a participant continuously maintained a platelet count \>=50 Gi/L was calculated and summarized for the first 12 weeks of Part 1. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If a participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

Time frame:
From Baseline up to Week 12 of Part 1
Reported as:
Mean · Weeks
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 1
WeeksPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During the First 12 Weeks of Part 10.4 ± 1.503.3 ± 3.13
SecondaryNumber of Participants Who Required a Protocol-defined Rescue Treatment During Part 1

Rescue treatment is defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.

Time frame:
From Baseline up to Week 12 of Part 1
Reported as:
Number · Participants
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1
ParticipantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 1712
SecondaryNumber of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0=no bleeding; Grade 1=petechiae; Grade 2=mild blood loss; Grade 3=gross bleeding; Grade 4=debilitating blood loss. The WHO grades were dichotomized into the following categories: no bleeding=Grade 0; any bleeding=Grades 1 to 4; no clinically significant bleeding=Grades 0 to 1; clinically significant bleeding=Grades 2 to 4. Baseline was defined as the Day 1 assessment or the latest possible screening assessment.

Time frame:
From Baseline through Follow-up of Part 1
Reported as:
Number · Participants
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the World Health Organization (WHO) Bleeding Scale During Part 1
ParticipantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period) -Eltrombopag
Baseline, Any bleeding n=29,632045
Baseline, Significant bleeding n=29,63616
Week 1, Any bleeding n=29,631941
Week 1, Significant bleeding n=29,6338
Week 2, Any bleeding n=29,631933
Week 2, Significant bleeding n=29,6366
Week 3, Any bleeding n=28,621832
Week 3, Significant bleeding n=28,6237
Week 4, Any bleeding n=29, 622027
Week 4, Significant bleeding n=29, 6244
Week 5, Any bleeding n=27, 621822
Week 5, Significant bleeding n=27, 6225
Week 6, Any bleeding n=28, 621724
Week 6, Significant bleeding n=28, 6205
Week 7, Any bleeding n=28, 631420
Week 7, Significant bleeding n=28, 6311
Week 8, Any bleeding n=28, 631724
Week 8,Significant bleeding n=28, 6314
Week 9, Any bleeding n=27, 611824
Week 9, Significant bleeding n=27, 6134
Week 10, Any bleeding n=28, 621720
Week 10, Significant bleeding n=28, 6224
Week 11, Any bleeding n=28, 611626
Week 11, Significant bleeding n=28, 6138
Week 12, Any bleeding n=28, 611623
Week 12, Significant bleeding n=28, 6123
Follow-up Week 1, Any bleeding n=0,201
Follow-up Week 1, Significant bleeding n=0,200
Follow-up Week 2, Any bleeding n=0,201
Follow-up Week 2, Significant bleeding n=0,200
Follow-up Week 3, Any bleeding n=0,302
Follow-up Week 3, Significant bleeding n=0,301
Follow-up Week 4, Any bleeding n=0,101
Follow-up Week 4, Significant bleeding n=0,101
Any follow-up Week, Any bleeding n=0,302
Any Follow-up Week, Significant bleeding n=0,301
SecondaryNumber of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2

Participants who achieved a platelet count \>=50 Gi/L at any time during Part 2 (up to Week 24) were reported.

Time frame:
From Baseline up to Week 24 of Part 2
Reported as:
Number · Participants
Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Number of Participants Who Achieved a Platelet Count >=50 Gi/L at Any Time During Part 270
SecondaryNumber of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2

Platelet response was analyzed after Week 4 for the eltrombopag-only period to allow participants who had been randomized to placebo in the Randomized Period time to escalate to their optimal dose of eltrombopag. Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

Time frame:
From Week 4 up to Week 24 of Part 2
Reported as:
Mean · Weeks
Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 2
WeeksPart 2 (Open-Label Period) - Eltrombopag
Number of Weeks in Which Participants Achieved a Platelet Count >=50 Gi/L, Between Weeks 4 and 24 of Part 210 ± 7.67
SecondaryMaximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2

The maximum duration for which a participant continuously maintained a platelet count of \>=50 Gi/L was calculated and summarized for the 24 weeks of eltrombopag dosing (Part 2). Participants with non-weekly assessments were assumed to have maintained a positive response for each week between two assessments that had positive responses. If the participant achieved a positive response at an assessment and then achieved a negative response at the next assessment, then it was assumed that the participant had achieved a positive response for one day.

Time frame:
From Baseline up to Week 24 of Part 2
Reported as:
Mean · Weeks
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 2
WeeksPart 2 (Open-Label Period) - Eltrombopag
Maximum Duration for Which a Participant Continuously Maintained a Platelet Count of >=50 Gi/L During Part 28.6 ± 7.84
SecondaryNumber of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy

Participants who discontinued or had a sustained reduction of a baseline immune (idiopathic) thrombocytopenic purpura (ITP) medication during the 24 weeks of Part 2 (Open-Label Period) and without requiring subsequent rescue therapy. For participants randomized to placebo in Part 1, Baseline is defined as Week 13 of Part 1. For participants randomized to eltrombopag in Part 1, Baseline is defined as Day 1 of Part 1. A sustained reduction was defined as a reduction for 4 weeks or more.

Time frame:
From Baseline up to Week 24 of Part 2
Reported as:
Number · Participants
Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Number of Participants Who Reduced or Discontinued Baseline Concomitant ITP Medications During Part 2 Without Requiring Subsequent Rescue Therapy8
SecondaryNumber of Participants Who Required a Protocol-defined Rescue Treatment During Part 2

Rescue treatment was defined as either a new immune (idiopathic) thrombocytopenic purpura (ITP) medication, an increase in the dose of a concomitant ITP medication from Baseline, a platelet transfusion, or a splenectomy.

Time frame:
From Baseline up to Week 24 of Part 2
Reported as:
Number · Participants
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Number of Participants Who Required a Protocol-defined Rescue Treatment During Part 211
SecondaryNumber of Participants With Any Bleeding and Significant Bleeding as Assessed Using the WHO Bleeding Scale During Part 2

The WHO Bleeding Scale is a measure of bleeding severity with the following grades: Grade 0 = no bleeding, Grade 1 = petechiae, Grade 2 = mild blood loss, Grade 3 = gross bleeding and Grade 4 = debilitating blood loss. The WHO Grades were dichotomized into the following categories: no bleeding = Grade 0; any bleeding = Grade 1 to 4; no clinically significant bleeding = Grade 0 to 1; clinically significant bleeding = Grade 2 to 4.

Time frame:
From Baseline of Part 2 through Follow-up
Reported as:
Number · Participants
Number of Participants With Any Bleeding and Significant Bleeding as Assessed Using the WHO Bleeding Scale During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Baseline, Any bleeding n=8755
Baseline, Significant bleeding n=8717
Week 1, Any bleeding n=8629
Week 1, Significant bleeding n=863
Week 2, Any bleeding n=8522
Week 2, Significant bleeding n=852
Week 3, Any bleeding n=8620
Week 3, Significant bleeding n=861
Week 4, Any bleeding n=6820
Week 4, Significant bleeding n=684
Week 5, Any bleeding n=6121
Week 5, Significant bleeding n=614
Week 6, Any bleeding n=5517
Week 6, Significant bleeding n=553
Week 7, Any bleeding n=5214
Week 7, Significant bleeding n=521
Week 8, Any bleeding n=5217
Week 8, Significant bleeding n=524
Week 9, Any bleeding n=4511
Week 9, Significant bleeding n=451
Week 10, Any bleeding n=428
Week 10, Significant bleeding n=422
Week 11, Any bleeding n=4012
Week 11, Significant bleeding n=403
Week 12, Any bleeding n=6315
Week 12, Significant bleeding n=635
Week 13, Any bleeding n=309
Week 13, Significant bleeding n=302
Week 14, Any bleeding n=389
Week 14, Significant bleeding n=382
Week 15, Any bleeding n=4310
Week 15, Significant bleeding n=432
Week 16, Any bleeding n=4711
Week 16, Significant bleeding n=474
Week 17, Any bleeding n=3710
Week 17, Significant bleeding n=372
Week 18, Any bleeding n=338
Week 18, Significant bleeding n=331
Week 19, Any bleeding n=4415
Week 19, Significant bleeding n=442
Week 20, Any bleeding n=397
Week 20, Significant bleeding n=392
Week 21, Any bleeding n=4110
Week 21, Significant bleeding n=412
Week 22, Any bleeding n=347
Week 22, Significant bleeding n=343
Week 23, Any bleeding n=3615
Week 23, Significant bleeding n=362
Week 24, Any bleeding n=7919
Week 24, Significant bleeding n=795
Follow-up Week 1, Any bleeding n=298
Follow-up Week 1, Significant bleeding n=292
Follow-up Week 2, Any bleeding n=3725
Follow-up Week 2, Significant bleeding n=375
Follow-up Week 3, Any bleeding n=4017
Follow-up Week 3, Significant bleeding n=405
Follow-up Week 4, Any bleeding n=7023
Follow-up Week 4, Significant bleeding n=703
Any follow-up Week, Any bleeding n=7738
Any Follow-up Week, Significant bleeding n=778
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Day 1 of Treatment up to Week 13 of Part 1+ 1 day
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 1
ParticipantsPart 1 (Randmoized Period) -PlaceboPart 1 (Randomized Period) - Eltrombopag
Any AE2151
Any SAE45
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2

An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening; requires hospitalization or prolongation of existing hospitalization, results in disability or incapacity, or is a congenital anomaly or birth defect. Medical or scientific judgment should be exercised in other situations.

Time frame:
From Day 1 of Part 2 up to Week 24 of Part 2 + 1 day
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Any AE69
Any SAE9
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 1

Clinical chemistry parameters were summarized according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.0: Grade 0 (G0), none; Grade 1 (G1), mild; Grade 2 (G2), moderate; Grade 3 (G3), severe; Grade 4 (G4), life-threatening or disabling. Clinical chemistry parameters included: aspartate amino transferase (AST), alkaline phosphatase (ALP), total bilirubin, albumin, alanine amino transferase (ALT), prothrombin international normalized ratio (PT INR), activated partial thromboplastin time (APTT), and creatinine. The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as Baseline. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.

Time frame:
From Baseline up to Week 13 of Part 1
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 1
ParticipantsPart 1 (Randmoized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
AST, G0, n=29, 632650
AST, G1, n=29, 63312
AST, G2, n=29, 6301
AST, G3, n=29, 6300
AST, G4, n=29, 6300
ALT, G0, n=29, 632752
ALT, G1, n=29, 6326
ALT, G2, n=29, 6303
ALT, G3, n=29, 6302
ALT, G4, n=29, 6300
Total Bilirubin, G0, n=29, 632960
Total Bilirubin, G1, n=29, 6303
Total Bilirubin, G2, n=29, 6300
Total Bilirubin, G3, n=29, 6300
Total Bilirubin, G4, n=29, 6300
Albumin, G0, n=29, 632963
Albumin, G1, n=29, 6300
Albumin, G2, n=29, 6300
Albumin, G3, n=29, 6300
Albumin, G4, n=29, 6300
ALP, G0, n=29, 632847
ALP, G1, n=29, 63116
ALP, G2, n=29, 6300
ALP, G3, n=29, 6300
ALP, G4, n=29, 6300
PT INR, G0, n=27, 582657
PT INR, G1, n=27, 5811
PT INR, G2, n=27, 5800
PT INR, G3, n=27, 5800
PT INR, G4, n=27, 5800
APTT, G0 n=27, 581324
APTT, G1, n=27, 581332
APTT, G2, n=27, 5812
APTT, G3, n=27, 5800
APTT, G4, n=27, 5800
Creatinine, G0, n=29, 632247
Creatinine, G1, n=29, 63715
Creatinine, G2, n=29, 6301
Creatinine, G3, n=29, 6300
Creatinine, G4, n=29, 6300
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2

Clinical chemistry parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Clinical chemistry parameters included: AST, ALP, total bilirubin, albumin, ALT, and creatinine. For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For serum creatinine, the value taken at Week 13 of Part 1 will be used as BL. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For serum creatinine, due to the variations in creatinine, the average of the Screening and the Day 1 values will be used as BL. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.

Time frame:
From Baseline (BL) of Part 2 through Follow-up
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Clinical Chemistry Parameters at Any Time Post-Baseline During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
AST, G063
AST, G121
AST, G21
AST, G32
AST, G40
ALT, G067
ALT, G114
ALT, G23
ALT, G33
ALT, G40
Total Bilirubin, G080
Total Bilirubin, G14
Total Bilirubin, G23
Total Bilirubin, G30
Total Bilirubin, G40
Albumin, G085
Albumin, G11
Albumin, G21
Albumin, G30
Albumin, G40
ALP, G067
ALP, G120
ALP, G20
ALP, G30
ALP, G40
Creatinine, G072
Creatinine, G114
Creatinine, G21
Creatinine, G30
Creatinine, G40
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 1

Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none; G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). The Baseline value is defined as the value taken at Day 1 or, if missing, the latest non-missing Screening value. The maximum post-Baseline toxicity grade includes any scheduled or unscheduled post-Baseline assessment during Part 1.

Time frame:
From Baseline up to Week 13 of Part 1
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 1
ParticipantsPart 1(Randomized Period)-PlaceboPart 1 (Randomized Period) - Eltrombopag
Leukocytes, G0, n=29, 632350
Leukocytes, G1, n=29, 63611
Leukocytes, G2, n=29, 6300
Leukocytes, G3, n=29, 6301
Leukocytes, G4, n=29, 6301
Neutrophils G0, n=29, 632752
Neutrophils G1, n=29, 6313
Neutrophils G2, n=29, 6306
Neutrophils G3, n=29, 6310
Neutrophils G4, n=29, 6302
Hemoglobin (increased), G0, n=29, 632649
Hemoglobin (increased), G1, n=29, 63312
Hemoglobin (increased), G2, n=29, 6302
Hemoglobin (increased), G3, n=29, 6300
Hemoglobin (increased), G4, n=29, 6300
Hemoglobin (anemia), G0, n=29, 632042
Hemoglobin (anemia), G1, n=29, 63717
Hemoglobin (anemia), G2, n=29, 6304
Hemoglobin (anemia), G3, n=29, 6320
Hemoglobin (anemia), G4, n=29, 6300
Lymphocytes (increased), G0, n=29, 631737
Lymphocytes (increased), G1, n=29, 6300
Lymphocytes (increased), G2, n=29, 631226
Lymphocytes (increased), G3, n=29, 6300
Lymphocytes (increased), G4, n=29, 6300
Lymphocytes (decreased), G0, n=29, 632548
Lymphocytes (decreased), G1, n=29, 63413
Lymphocytes (decreased), G2, n=29, 6301
Lymphocytes (decreased), G3, n=29, 6301
Lymphocytes (decreased), G4, n=29, 6300
SecondaryNumber of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2

Hematology parameters were summarized according to the NCI CTCAE, version 4.0: G0, none, G1, mild; G2, moderate; G3, severe; G4, life-threatening or disabling. Hematology parameters included: leukocytes, neutrophils, hemoglobin (increased), hemoglobin (anemia), lymphocytes (increased), and lymphocytes (decreased). For participants randomized to Placebo in Part 1, the BL value for Part 2 is defined as the value taken at Week 13 of Part 1. For participants randomized to Eltrombopag in Part 1, the BL value is defined as the value taken on Day 1 or, if missing, the latest non-missing Screening value. For participants who do not have both a Screening and Day 1 value, the Screening or Day 1 value will be used as BL. The maximum post-BL toxicity grade includes any scheduled or unscheduled post-BL assessment.

Time frame:
From Baseline up to Week 24 of Part 2 and Follow-up Weeks 1 to 4 (up to Study Week 41)
Reported as:
Number · Participants
Number of Participants With the Indicated Maximum Toxicity Grade for the Indicated Hematology Parameters at Any Time Post-Baseline During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Leukocytes, G059
Leukocytes, G123
Leukocytes, G23
Leukocytes, G32
Leukocytes, G40
Neutrophils, G063
Neutrophils, G16
Neutrophils, G213
Neutrophils, G32
Neutrophils, G43
Hemoglobin (increased), G074
Hemoglobin (increased), G111
Hemoglobin (increased), G22
Hemoglobin (increased), G30
Hemoglobin (increased), G40
Hemoglobin (anemia), G048
Hemoglobin (anemia), G131
Hemoglobin (anemia), G27
Hemoglobin (anemia), G31
Hemoglobin (anemia), G40
Lymphocytes (increased), G047
Lymphocytes (increased), G10
Lymphocytes (increased), G240
Lymphocytes (increased), G30
Lymphocytes (increased), G40
Lymphocytes (decreased), G065
Lymphocytes (decreased), G119
Lymphocytes (decreased), G22
Lymphocytes (decreased), G31
Lymphocytes (decreased), G40
SecondaryNumber of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 1

Vital sign measurements were taken before any blood draws and included systolic blood pressure(SBP), diastolic blood pressure(DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard reference ranges RR as reference range high(RRH) and reference range low(RRL). The Baseline(BL) value is defined as the value taken at Day 1 or if missing, the latest non-missing SCR value. RR for Blood Pressure (mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120;, DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR(bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.

Time frame:
From Screening (SCR) up to Week 13 of Part 1
Reported as:
Number · Participants
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 1
ParticipantsPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period)-Eltrombopag
DBP, Day 1, RRH, n=28,6268
DBP, Day 1, RRL, n=28, 6225
DBP, Week 1, RRH, n=28, 63310
DBP, Week 1, RRL, n=28, 6305
DBP, Week 2, RRH, n=29, 6338
DBP, Week 2, RRL, n=29, 6326
DBP, Week 3, RRH, n=28, 63712
DBP, Week 3, RRL, n=28, 6326
DBP, Week 4, RRH, n=29, 6275
DBP, Week 4, RRL, n=29, 6229
DBP, Week 5, RRH, n=27, 62410
DBP, Week 5, RRL, n=27, 6226
DBP, Week 6, RRH, n=28, 62710
DBP, Week 6, RRL, n=28, 6218
DBP, Week 7, RRH, n=28, 6337
DBP, Week 7, RRL, n=28, 6325
DBP, Week 8, RRH, n=28, 6349
DBP, Week 8, RRL, n=28, 6328
DBP, Week 9, RRH, n=27, 6149
DBP, Week 9, RRL, n=27, 6124
DBP, Week 10, RRH, n=28, 6268
DBP, Week 10, RRL, n=28, 6227
DBP, Week 11, RRH, n=28, 6168
DBP, Week 11, RRL, n=28, 6136
DBP, Week 12, RRH, n=28, 6138
DBP, Week 12, RRL, n=28, 6106
DBP, Week 13, RRH, n=28, 6149
DBP, Week 13, RRL, n=28, 6134
Heart Rate, Day 1, RRH, n=28, 6202
Heart Rate, Day 1, RRL, n=28, 6201
Heart Rate, Week 1, RRH, n=28, 6300
Heart Rate, Week 1, RRL, n=28, 6300
Heart Rate, Week 2, RRH, n=29, 6321
Heart Rate, Week 2, RRL, n=29, 6301
Heart Rate, Week 3, RRH, n=28, 6312
Heart Rate, Week 3, RRL, n=28, 6300
Heart Rate, Week 4, RRH, n=29, 6104
Heart Rate, Week 4, RRL, n=29, 6101
Heart Rate, Week 5, RRH, n=27, 6215
Heart Rate, Week 5, RRL, n=27, 6210
Heart Rate, Week 6, RRH, n=28,6211
Heart Rate, Week 6, RRL, n=28, 6210
Heart Rate, Week 7, RRH, n=28, 6302
Heart Rate, Week 7, RRL, n=28, 6310
Heart Rate, Week 8, RRH, n=28, 6312
Heart Rate, Week 8, RRL, n=28, 6310
Heart Rate, Week 9, RRH, n=27, 6112
Heart Rate, Week 9, RRL, n=27, 6100
Heart Rate, Week 10, RRH, n=28, 6211
Heart Rate, Week 10, RRL, n=28, 6200
Heart Rate, Week 11, RRH, n=28, 6112
Heart Rate, Week 11, RRL, n=28, 6100
Heart Rate, Week 12, RRH, n=28,6102
Heart Rate, Week 12, RRL, n=28, 6100
Heart Rate, Week 13, RRH, n=28, 6103
Heart Rate, Week 13, RRL, n=28, 6110
SBP, Day 1, RRH, n=28, 62510
SBP, Day 1, RRL, n=28, 6236
SBP, Week 1, RRH, n=28, 63311
SBP, Week 1, RRL, n=28,6348
SBP, Week 2, RRH, n=29, 6347
SBP, Week 2, RRL, n=29, 6339
SBP, Week 3, RRH, n=28, 6339
SBP, Week 3, RRL, n=28, 6329
SBP, Week 4, RRH, n=29, 62310
SBP, Week 4, RRL, n=29, 6229
SBP, Week 5, RRH, n=27, 6259
SBP, Week 5, RRL, n=27, 6247
SBP, Week 6, RRH, n=28, 6257
SBP, Week 6, RRL, n=28, 6238
SBP, Week 7, RRH, n=28, 63510
SBP, Week 7, RRL, n=28, 6337
SBP, Week 8, RRH, n=28, 63314
SBP, Week 8, RRL, n=28, 6347
SBP, Week 9, RRH, n=27, 61412
SBP, Week 9, RRL, n=27, 6137
SBP, Week 10, RRH, n=28, 62411
SBP, Week 10, RRL, n=28, 62311
SBP, Week 11, RRH, n=28, 61612
SBP, Week 11, RRL, n=28, 6159
SBP, Week 12, RRH, n=28, 61411
SBP, Week 12, RRL, n=28, 6144
SBP, Week 13, RRH, n=28, 6169
SBP, Week 13, RRL, n=28, 6147
SecondaryNumber of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 2

Vital sign measurements were taken before any blood draw and included systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate(HR). The number of participants are reported with vital sign data falling outside the standard RR as reference range high(RRH) and reference range low(RRL) from SCR up to Week 24 of Part 2 and from Follow-up Week 1 to Week 4. RR for Blood Pressure(mmHg) are read as: Lower Limit of Normal, Normal Range, Upper Limit of Normal. For Ages 1 to 5 years (yrs) ranges are SBP \<85, 85 to 115, \>115; DBP \<45, 45 to70, \>70. Ages 6 to 11 yrs: SBP \<85, 85 to 120, \>120; DBP \<50, 50 to 75, \>75. Ages 12 to 17 yrs: SBP \<95, 95 to 135, \>135; DBP \<55, 55 to 85, \>85. RR for HR (bpm) are ages 1 to \< 3 yrs: \<90, 90 to 140, \>140; ages 3 to \< 5 yrs: \<75, 75 to 130, \>130, ages 5 to \< 8yrs: \<65, 65 to 115, \>115; ages 8 to \< 12yrs: \<55, 55 to 110, \>110; and ages 12 to 18 yrs: \<55, 55 to 110, \>110.

Time frame:
From Week 1 up to Week 24 of Part 2 and Follow-up Week 1 to Week 4 (up to Week 41)
Reported as:
Number · Participants
Number of Participants With Vital Sign Data Falling Outside the Reference Ranges (RR) at the Indicated Visit During Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
DBP, Week 1, RRH, n=8714
DBP, Week 1, RRL, n=878
DBP, Week 2, RRH, n=8614
DBP, Week 2, RRL, n=868
DBP, Week 3, RRH, n=8613
DBP, Week 3, RRL, n=8611
DBP, Week 4, RRH, n=6810
DBP, Week 4, RRL, n=687
DBP, Week 5, RRH, n=617
DBP, Week 5, RRL, n=617
DBP, Week 6, RRH, n=556
DBP, Week 6, RRL, n=554
DBP, Week 7, RRH, n=527
DBP, Week 7, RRL, n=525
DBP, Week 8, RRH, n=534
DBP, Week 8, RRL, n=536
DBP, Week 9, RRH, n=453
DBP, Week 9, RRL, n=457
DBP, Week 10, RRH, n=425
DBP, Week 10, RRL, n=427
DBP, Week 11, RRH, n=405
DBP, Week 11, RRL, n=407
DBP, Week 12, RRH, n=639
DBP, Week 12, RRL, n=6311
DBP, Week 13, RRH, n=294
DBP, Week 13, RRL, n=292
DBP, Week 14, RRH, n=382
DBP, Week 14, RRL, n=389
DBP, Week 15, RRH, n=437
DBP, Week 15, RRL, n=433
DBP, Week 16, RRH, n=473
DBP, Week 16, RRL, n=476
DBP, Week 17, RRH, n=375
DBP, Week 17, RRL, n=376
DBP, Week 18, RRH, n=347
DBP, Week 18, RRL, n=345
DBP, Week 19, RRH, n=445
DBP, Week 19, RRL, n=443
DBP, Week 20, RRH, n=396
DBP, Week 20, RRL, n=393
DBP, Week 21, RRH, n=419
DBP, Week 21, RRL, n=416
DBP, Week 22, RRH, n=346
DBP, Week 22, RRL, n=343
DBP, Week 23, RRH, n=366
DBP, Week 23, RRL, n=366
DBP, Week 24, RRH, n=7914
DBP, Week 24, RRL, n=7910
DBP, Follow-Up Week 1, RRH, n=298
DBP, Follow-Up Week 1, RRL, n=293
DBP, Follow-Up Week 2, RRH, n=378
DBP, Follow-Up Week 2, RRL, n=376
DBP, Follow-Up Week 3, RRH, n=394
DBP, Follow-Up Week 3, RRL, n=395
DBP, Follow-Up Week 4, RRH, n=678
DBP, Follow-Up Week 4, RRL, n=675
Heart Rate, Week 1, RRH, n=874
Heart Rate, Week 1, RRL, n=871
Heart Rate, Week 2, RRH, n=863
Heart Rate, Week 2, RRL, n=862
Heart Rate, Week 3, RRH, n=861
Heart Rate, Week 3, RRL, n=860
Heart Rate, Week 4, RRH, n=682
Heart Rate, Week 4, RRL, n=680
Heart Rate, Week 5, RRH, n=610
Heart Rate, Week 5, RRL, n=611
Heart Rate, Week 6, RRH, n=551
Heart Rate, Week 6, RRL, n=550
Heart Rate, Week 7, RRH, n=522
Heart Rate, Week 7, RRL, n=520
Heart Rate, Week 8, RRH, n=532
Heart Rate, Week 8, RRL, n=530
Heart Rate, Week 9, RRH, n=452
Heart Rate, Week 9, RRL, n=450
Heart Rate, Week 10, RRH, n=421
Heart Rate, Week 10, RRL, n=421
Heart Rate, Week 11, RRH, n=401
Heart Rate, Week 11, RRL, n=401
Heart Rate, Week 12, RRH, n=631
Heart Rate, Week 12, RRL, n=631
Heart Rate, Week 13, RRH, n=292
Heart Rate, Week 13, RRL, n=290
Heart Rate, Week 14, RRH, n=382
Heart Rate, Week 14, RRL, n=381
Heart Rate, Week 15, RRH, n=430
Heart Rate, Week 15, RRL, n=430
Heart Rate, Week 16, RRH, n=472
Heart Rate, Week 16, RRL, n=470
Heart Rate, Week 17, RRH, n=372
Heart Rate, Week 17, RRL, n=371
Heart Rate, Week 18, RRH, n=340
Heart Rate, Week 18, RRL, n=340
Heart Rate, Week 19, RRH, n=440
Heart Rate, Week 19, RRL, n=441
Heart Rate, Week 20, RRH, n=392
Heart Rate, Week 20, RRL, n=390
Heart Rate, Week 21, RRH, n=410
Heart Rate, Week 21, RRL, n=410
Heart Rate, Week 22, RRH, n=342
Heart Rate, Week 22, RRL, n=340
Heart Rate, Week 23, RRH, n=360
Heart Rate, Week 23, RRL, n=360
Heart Rate, Week 24, RRH, n=791
Heart Rate, Week 24, RRL, n=791
Heart Rate, Follow-Up Week 1, RRH, n=291
Heart Rate, Follow-Up Week 1, RRL, n=290
Heart Rate, Follow-Up Week 2, RRH, n=372
Heart Rate, Follow-Up Week 2, RRL, n=371
Heart Rate, Follow-Up Week 3, RRH, n=392
Heart Rate, Follow-Up Week 3, RRL, n=390
Heart Rate, Follow-Up Week 4, RRH, n=672
Heart Rate, Follow-Up Week 4, RRL, n=672
SBP, Week 1, RRH, n=8713
SBP, Week 1, RRL, n=879
SBP, Week 2, RRH, n=8619
SBP, Week 2, RRL, n=8616
SBP, Week 3, RRH, n=8615
SBP, Week 3, RRL, n=8613
SBP, Week 4, RRH, n=6810
SBP, Week 4, RRL, n=687
SBP, Week 5, RRH, n=617
SBP, Week 5, RRL, n=618
SBP, Week 6, RRH, n=5511
SBP, Week 6, RRL, n=557
SBP, Week 7, RRH, n=5210
SBP, Week 7, RRL, n=525
SBP, Week 8, RRH, n=538
SBP, Week 8, RRL, n=535
SBP, Week 9, RRH, n=458
SBP, Week 9, RRL, n=459
SBP, Week 10, RRH, n=424
SBP, Week 10, RRL, n=424
SBP, Week 11, RRH, n=404
SBP, Week 11, RRL, n=406
SBP, Week 12, RRH, n=6314
SBP, Week 12, RRL, n=6310
SBP, Week 13, RRH, n=293
SBP, Week 13, RRL, n=292
SBP, Week 14, RRH, n=385
SBP, Week 14, RRL, n=387
SBP, Week 15, RRH, n=439
SBP, Week 15, RRL, n=437
SBP, Week 16, RRH, n=477
SBP, Week 16, RRL, n=476
SBP, Week 17, RRH, n=379
SBP, Week 17, RRL, n=374
SBP, Week 18, RRH, n=346
SBP, Week 18, RRL, n=345
SBP, Week 19, RRH, n=447
SBP, Week 19, RRL, n=444
SBP, Week 20, RRH, n=395
SBP, Week 20, RRL, n=395
SBP, Week 21, RRH, n=4110
SBP, Week 21, RRL, n=416
SBP, Week 22, RRH, n=346
SBP, Week 22, RRL, n=344
SBP, Week 23, RRH, n=366
SBP, Week 23, RRL, n=363
SBP, Week 24, RRH, n=7913
SBP, Week 24, RRL, n=7912
SBP, Follow-Up Week 1, RRH, n=295
SBP, Follow-Up Week 1, RRL, n=293
SBP, Follow-Up Week 2, RRH, n=375
SBP, Follow-Up Week 2, RRL, n=377
SBP, Follow-Up Week 3, RRH, n=399
SBP, Follow-Up Week 3, RRL, n=394
SBP, Follow-Up Week 4, RRH, n=679
SBP, Follow-Up Week 4, RRL, n=677
SecondaryNumber of Participants With a Change in Visual Acuity Since Baseline at Week 12 of Part 1

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No (no change from Baseline), Not Clinically Significant (NCS), Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

Time frame:
Baseline and Week 12 of Part 1
Reported as:
Number · Participants
Number of Participants With a Change in Visual Acuity Since Baseline at Week 12 of Part 1
ParticipantsEPart 1 (Randomized Period)-PlaceboPart 1 (Randomized Period)-Eltrombopag
No Change2247
NCS48
Improvement12
Worsening01
Not Measured25
SecondaryNumber of Participants With a Change in Visual Acuity Since Baseline at Week 24 of Part 2

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

Time frame:
Baseline and Week 24 of Part 2
Reported as:
Number · Participants
Number of Participants With a Change in Visual Acuity Since Baseline at Week 24 of Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
No Change58
NCS13
Improvement3
Worsening6
Not Measured7
SecondaryNumber of Participants With a Change in Visual Acuity Since Baseline at Follow-Up Week 24

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. Change in visual acuity results are presented as No Change, NCS, Improvement, and Worsening since Baseline. The Baseline value was obtained at the Screening Visit.

Time frame:
Baseline and Follow-Up Week 24 (Study Week 61)
Reported as:
Number · Participants
Number of Participants With a Change in Visual Acuity Since Baseline at Follow-Up Week 24
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
No Change63
NCS12
Improvement9
Worsening2
Not Measured1
SecondaryNumber of Participants With Worsening Visual Acuity Due to Cataracts at Week 12 of Part 1

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 12 of Part 1 are presented. Change due to cataracts is categorized as "Yes" or "No."

Time frame:
Baseline and Week 12 of Part 1
Reported as:
Number · Participants
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 12 of Part 1
ParticipantsPart 1 (Randomized Period) - PlaceboPart 1 (Randomized Period) - Eltrombopag
Yes—0
No—1
SecondaryNumber of Participants With Worsening Visual Acuity Due to Cataracts at Week 24 of Part 2

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Week 24 of Part 2 are presented. Change due to cataracts is categorized as "Yes" or "No.

Time frame:
Baseline and Week 24 of Part 2
Reported as:
Number · Participants
Number of Participants With Worsening Visual Acuity Due to Cataracts at Week 24 of Part 2
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Yes1
No5
SecondaryNumber of Participants With Worsening Visual Acuity Due to Cataracts at Follow-Up Week 24

The visual acuity assessment was performed by an ophthalmologist or an optometrist under the guidance of an ophthalmologist. Visual acuity is defined as acuteness or clearness of vision. The number of participants with worsening visual acuity due to cataracts at Follow-up Week 24 are presented. Change due to cataracts is categorized as "Yes" or "No."

Time frame:
Baseline and Follow-Up Week 24 (Week 61)
Reported as:
Number · Participants
Number of Participants With Worsening Visual Acuity Due to Cataracts at Follow-Up Week 24
ParticipantsPart 2 (Open-Label Period) - Eltrombopag
Yes0
No2
SecondaryPharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)

Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. AUC(0-t) is defined as the area under the concentration-time curve over the dosing interval. The AUC(0-t) for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Reported as:
Geometric mean · micrograms*hour per milliliter (ug.h/mL)
Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)
micrograms*hour per milliliter (ug.h/mL)Eltrombopag Cohort 1 (12-17 Years)Eltrombopag Cohort 2 (6-11 Years)Eltrombopag Cohort 3 (1-5 Years)
Pharmacokinetic (PK) Assessments for Eltrombopag for AUC (0-t)104 (86.1 to 126)171 (147 to 200)184 (147 to 230)
SecondaryPharmacokinetic (PK) Assessments for Eltrombopag for Cmax

Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Cmax is defined as the maximum observed concentration. The Cmax for a 50mg dose was estimated for each cohort. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort for a 50mg dose.

Time frame:
Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Reported as:
Geometric mean · micrograms per milliliter (ug/mL)
Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax
micrograms per milliliter (ug/mL)Eltrombopag Cohort 1 (12-17 Years)Eltrombopag Cohort 2 (6-11 Years)Eltrombopag Cohort 3 (1-5 Years)
Pharmacokinetic (PK) Assessments for Eltrombopag for Cmax6.94 (5.96 to 8.08)11.2 (9.91 to 12.8)12.5 (10.7 to 14.6)
SecondaryPharmacokinetic (PK) Assessments for Eltrombopag for Apparent Oral Clearance (CL/F) and Apparent Intercompartmental Clearance (Q/F)

Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. CL/F is defined as the apparent oral clearance from plasma and Q/F is defined as apparent intercompartmental clearance. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.

Time frame:
Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Reported as:
Geometric mean · Liters per hour (L/hr)
Pharmacokinetic (PK) Assessments for Eltrombopag for Apparent Oral Clearance (CL/F) and Apparent Intercompartmental Clearance (Q/F)
Liters per hour (L/hr)Eltrombopag Cohort 1 (12-17 Years)Eltrombopag Cohort 2 (6-11 Years)Eltrombopag Cohort 3 (1-5 Years)
CL/F0.48 (0.40 to 0.58)0.29 (0.25 to 0.34)0.19 (0.15 to 0.24)
Q/F0.61 (0.54 to 0.68)0.38 (0.34 to 0.42)0.24 (0.20 to 0.28)
SecondaryPK Assessments for Eltrombopag for Apparent Central Volume (Vc/F) and Apparent Peripheral Volume (Vp/F)

Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Vc/F is defined as the volume of the central (e.g. plasma) compartment and Vp/F is defined as the volume of the peripheral compartment. These parameters are dose independent. From the final model, a single value of each PK parameter was estimated for each subject, and geometric mean (95% CI) values are presented for each cohort.

Time frame:
Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Reported as:
Geometric mean · Liters (L)
PK Assessments for Eltrombopag for Apparent Central Volume (Vc/F) and Apparent Peripheral Volume (Vp/F)
Liters (L)Eltrombopag Cohort 1 (12-17 Years)Eltrombopag Cohort 2 (6-11 Years)Eltrombopag Cohort 3 (1-5 Years)
Vc/F2.46 (2.20 to 2.75)1.57 (1.35 to 1.81)0.90 (0.76 to 1.05)
Vp/F19.2 (17.7 to 20.9)11.8 (10.9 to 12.9)7.17 (6.58 to 7.81)
SecondaryPopulation PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)

Single PK samples were collected at each visit during Part 1 Weeks 2, 4, 6, 8, 10, 12 and at each weekly or monthly visit during Part 2 Weeks 1-12 (Study Weeks 13-37). The concentration data were pooled across visits to identify population PK and variability parameter estimates and covariate effects. Ka is defined as the absorption rate constant. This parameter is dose independent, and the population estimate Ka is reported.

Time frame:
Part 1 Weeks 2, 4, 6, 8, 10, 12, and Part 2 Weeks 1-12 (Study Weeks 13 - 37)
Reported as:
Number · 1/h
Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)
1/hEltrombopag Cohort 1 (12-17 Years)Eltrombopag Cohort 2 (6-11 Years)Eltrombopag Cohort 3 (1-5 Years)
Population PK Model Point Estimate for Eltrombopag for Absorption Rate-constant (Ka)0.1890.1890.189

Adverse events

Collected over On-treatment adverse events (AEs) and serious adverse events (SAEs) are defined as events occuring from the start of investigational product until follow up (up to 61 weeks).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Eltrombopag—5/63 (7.9%)51/63 (81%)
Part 1: Placebo—4/29 (13.8%)19/29 (65.5%)
Part 2: Eltrombopag—9/87 (10.3%)68/87 (78.2%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart 1: EltrombopagPart 1: PlaceboPart 2: Eltrombopag
EpistaxisRespiratory, thoracic and mediastinal disorders0/631/292/87
PetechiaeSkin and subcutaneous tissue disorders0/631/290/87
HaemorrhageVascular disorders0/631/290/87
Hypertensive crisisVascular disorders0/631/290/87
GingivitisInfections and infestations1/630/290/87
InfluenzaInfections and infestations1/630/290/87
Meningitis asepticInfections and infestations1/630/290/87
PneumoniaInfections and infestations1/630/291/87
Pneumonia fungalInfections and infestations1/630/290/87
Alanine aminotransferase abnormalInvestigations1/630/290/87
Most frequent other events
Showing 10 of 140
Most frequent other events
EventPart 1: EltrombopagPart 1: PlaceboPart 2: Eltrombopag
NasopharyngitisInfections and infestations11/632/297/87
EpistaxisRespiratory, thoracic and mediastinal disorders8/635/2911/87
RhinitisInfections and infestations10/632/293/87
Abdominal pain upperGastrointestinal disorders3/634/293/87
CoughRespiratory, thoracic and mediastinal disorders7/630/298/87
Upper respiratory tract infectionInfections and infestations7/631/299/87
HeadacheNervous system disorders6/633/298/87
PyrexiaGeneral disorders4/631/299/87
VomitingGastrointestinal disorders2/633/296/87
Abdominal painGastrointestinal disorders6/630/297/87

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboEltrombopagTotal
Mean9.8 ± 4.009.4 ± 4.439.6 ± 4.22
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboEltrombopagTotal
Female143044
Male153348
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboEltrombopagTotal
African American/African Heritage011
Central/South Asian Heritage011
Japanese/East Asian/South East Asian Heritage102030
Arabic/North African Heritage123
White/Caucasian/European Heritage183856
Mixed Race011
08

Study locations

51 sites
  • GSK Investigational Site
    Los Angeles, California 90027, United States
  • GSK Investigational Site
    St. Petersburg, Florida 33701, United States
  • GSK Investigational Site
    Brooklyn, New York 11219, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84113, United States
  • GSK Investigational Site
    Capital Federal, Buenos Aires 1425, Argentina
  • GSK Investigational Site
    Brno, 613 00, Czech Republic
  • GSK Investigational Site
    Olomouc, 775 20, Czech Republic
  • GSK Investigational Site
    Ostrava, 708 52, Czech Republic
  • GSK Investigational Site
    Praha 5, 154 00, Czech Republic
  • GSK Investigational Site
    Freiburg, Baden-Wuerttemberg 79106, Germany
  • GSK Investigational Site
    Mainz, Rheinland-Pfalz 55131, Germany
  • GSK Investigational Site
    Berlin, 13353, Germany
  • GSK Investigational Site
    Pokfulam, Hong Kong
  • GSK Investigational Site
    Shatin, Hong Kong
  • GSK Investigational Site
    Beer-Sheva, 84101, Israel
  • GSK Investigational Site
    Haifa, 31048, Israel
  • GSK Investigational Site
    Petah-Tikva, 49202, Israel
  • GSK Investigational Site
    Ramat Gan, 52621, Israel
  • GSK Investigational Site
    Rehovot, 76100, Israel
  • GSK Investigational Site
    Tel-Aviv, 64239, Israel
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Roma, Lazio 00165, Italy
  • GSK Investigational Site
    Monza, Lombardia 20900, Italy
  • GSK Investigational Site
    Torino, Piemonte 10126, Italy
  • GSK Investigational Site
    Bydgoszcz, Poland
  • GSK Investigational Site
    Gdansk, 80-952, Poland
  • GSK Investigational Site
    Lodz, 91-738, Poland
  • GSK Investigational Site
    Lublin, 20-093, Poland
  • GSK Investigational Site
    Krasnodar, 350007, Russian Federation
  • GSK Investigational Site
    Moscow, 105077, Russian Federation
  • GSK Investigational Site
    Moscow, 117198, Russian Federation
  • GSK Investigational Site
    Saint Petersburg, 198205, Russian Federation
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, Spain
  • GSK Investigational Site
    Murcia (El Palmar), 30120, Spain
  • GSK Investigational Site
    Málaga, 29011, Spain
  • GSK Investigational Site
    Pamplona, 31008, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Tainan, 704, Taiwan
  • GSK Investigational Site
    Taoyuan, 333, Taiwan
  • GSK Investigational Site
    Bangkok, 10330, Thailand
  • GSK Investigational Site
    Bangkok, Thailand
  • GSK Investigational Site
    Khon Kaen, 40002, Thailand
  • GSK Investigational Site
    Songkla, 90110, Thailand
  • GSK Investigational Site
    Birmingham, B4 6NH, United Kingdom
  • GSK Investigational Site
    Cardiff, CF14 4XW, United Kingdom
  • GSK Investigational Site
    London, SW17 0QT, United Kingdom
  • GSK Investigational Site
    Manchester, M13 9WL, United Kingdom
  • GSK Investigational Site
    Romford, RM7 0AG, United Kingdom
  • GSK Investigational Site
    Sheffield, S10 2TH, United Kingdom
09

References and documents

Publications

  • Wire MB, Li X, Zhang J, Sallas W, Aslanis V, Ouatas T. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia. Clin Pharmacol Ther. 2018 Dec;104(6):1199-1207. doi: 10.1002/cpt.1066. Epub 2018 Apr 17. PubMed 29536526 ↗
  • Grainger JD, Locatelli F, Chotsampancharoen T, Donyush E, Pongtanakul B, Komvilaisak P, Sosothikul D, Drelichman G, Sirachainan N, Holzhauer S, Lebedev V, Lemons R, Pospisilova D, Ramenghi U, Bussel JB, Bakshi KK, Iyengar M, Chan GW, Chagin KD, Theodore D, Marcello LM, Bailey CK. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015 Oct 24;386(10004):1649-58. doi: 10.1016/S0140-6736(15)61107-2. Epub 2015 Jul 28. Erratum In: Lancet. 2015 Oct 24;386(10004):1630. doi: 10.1016/S0140-6736(15)00539-5. PubMed 26231455 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Jan 2014 and a completion of Jan 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2014, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2011
First posted
Jan 30, 2012
Start
Mar 2012
Primary completionActual
Jan 2014
CompletionActual
Jan 2014
Results first posted
Sep 29, 2014
Last update
Mar 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01520909
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 30, 2012
Start date
Mar 2012
Primary completion
Jan 2014
Completion
Jan 2014
Results posted
Sep 29, 2014
Last update
Mar 10, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eltrombopag

Start the discussion